REVEAL OPPORTUNITIES TO ENHANCE DIAGNOSTICS

Discover how to potentially improve your diagnostic outcomes and efficiency with the DEFINITY® EchoInsights Calculator^1-4

Knowing the number of suboptimal transthoracic echocardiograms (TTEs) that may be improved with the use of an ultrasound enhancing agent (UEA) gives you information you can use to refine your institution’s process.^5,6

Fields marked * are required.

First Name

Last Name

Facility Name

Zip Code

Email Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

How we will use this information:

Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, email address, telephone number, and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. Lantheus Medical Imaging may also collect data entered as a necessity of engaging with any online tools or resources. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes. Within Lantheus Medical Imaging, data may be transferred to or accessed by authorized Lantheus Medical Imaging personnel in other countries.

If at any time you do not wish to be contacted by Lantheus Medical Imaging, or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

INDICATION

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY^® administration.
Always have resuscitation equipment and trained personnel readily available.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration.
Always have resuscitation equipment and trained personnel readily available.

CONTRAINDICATIONS:

Contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

WARNINGS AND PRECAUTIONS:

Serious Cardiopulmonary Reactions have occurred during or following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

Serious Hypersensitivity Reactions have been observed during or shortly following administration including anaphylaxis, with manifestations that may include death. DEFINITY® contains PEG and may increase risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG. Clinically assess patients for prior hypersensitivity reactions to products containing PEG. Monitor all patients for hypersensitivity reactions.

Systemic Embolization may occur in patients with a cardiac shunt. Assess patients with shunts for embolic phenomena following administration. DEFINITY® is only for intravenous administration and must not be administered by intra-arterial injection.

There is a risk of Ventricular Arrhythmia Related to High Mechanical Index. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The maximum recommended mechanical index for use with DEFINITY® is 0.8 in adult patients and 0.3 in pediatric patients.

Acute Pain Episodes in Patients with Sickle Cell Disease (SCD) shortly following administration have been reported. Discontinue DEFINITY® in SCD patients experiencing new or worsening pain.

ADVERSE REACTIONS:

The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information and Important Safety Information, including boxed WARNING regarding serious cardiopulmonary reactions.

References:

Data on file, Lantheus.
DEFINITY®. Prescribing Information. Lantheus.
US Food and Drug Administration. DEFINITY drug approval letter(s). Accessed June 5, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/
nda/2001/21-064_Definity.cfm
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005
Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122. doi:10.1016/j.amjcard.2021.03.039
Fraiche AM, Manning WJ, Nagueh SF, Main ML, Markson LJ, Strom JB. Identification of need for ultrasound enhancing agent study (the IN-USE study). J Am Soc Echocardiogr. 2020;33(12):1500-1508. doi:10.1016/j.echo.2020.07.015

PM-US-DE-0781-V2 July 2025

DEFINITY® Customer Service 1.800.299.3431

BACK TO
TOP

REVEAL OPPORTUNITIES TO ENHANCE DIAGNOSTICS

Discover how to potentially improve your diagnostic outcomes and efficiency with the DEFINITY® EchoInsights Calculator1-4

INDICATION

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

DEFINITY® Customer Service 1.800.299.3431

DEFINITY® Customer Service 1.800.299.3431

Discover how to potentially improve your diagnostic outcomes and efficiency with the DEFINITY® EchoInsights Calculator^1-4

DEFINITY® Customer Service
1.800.299.3431